1. Home
  2. NGNE vs CARE Comparison

NGNE vs CARE Comparison

Compare NGNE & CARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurogene Inc.

NGNE

Neurogene Inc.

N/A

Current Price

$25.43

Market Cap

744.9M

Sector

Health Care

ML Signal

N/A

Logo Carter Bankshares Inc.

CARE

Carter Bankshares Inc.

N/A

Current Price

$28.61

Market Cap

723.5M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
NGNE
CARE
Founded
2003
1974
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
744.9M
723.5M
IPO Year
2014
2020

Fundamental Metrics

Financial Performance
Metric
NGNE
CARE
Price
$25.43
$28.61
Analyst Decision
Strong Buy
Hold
Analyst Count
10
4
Target Price
★ $77.88
$34.25
AVG Volume (30 Days)
★ 342.8K
164.7K
Earning Date
11-20-2026
10-29-2026
Dividend Yield
N/A
★ 1.40%
EPS Growth
0.93
★ 30.19
EPS
N/A
★ 5.53
Revenue
N/A
★ $20,315,000.00
Revenue This Year
N/A
$76.15
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$5.65
Revenue Growth
N/A
★ 4.65
52 Week Low
$15.93
$16.86
52 Week High
$43.66
$36.06

Technical Indicators

Market Signals
Indicator
NGNE
CARE
Relative Strength Index (RSI) 47.84 35.66
Support Level $24.88 $26.52
Resistance Level $28.47 $31.02
Average True Range (ATR) 2.50 0.77
MACD 0.38 -0.16
Stochastic Oscillator 35.88 8.99

Price Performance

Historical Comparison
NGNE
CARE

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

About CARE Carter Bankshares Inc.

Carter Bankshares Inc is a bank holding company that conducts its business solely through the bank. The Bank earns revenue from interest on loans and securities and fees charged for financial services provided to customers. It offers a full range of deposit services including Lifetime Free Checking, interest checking accounts, savings accounts, retirement accounts and other deposit accounts of various types, ranging from money market accounts to longer-term CDs. The Bank offers a full range of commercial and consumer loans. The Bank also originates and holds fixed and variable-rate mortgage loans and offers home equity lines of credit to its customers.

Share on Social Networks: